DaVita (DVA) Scheduled to Post Earnings on Thursday

DaVita (NYSE:DVA) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of $1.96 per share for the quarter. DaVita has set its FY24 guidance at $8.70-9.80 EPS and its FY 2024 guidance at 8.700-9.800 EPS.Parties interested in registering for the company’s conference call can do so using this link.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, February 13th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.53 by $0.34. The company had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.01 billion. DaVita had a net margin of 5.70% and a return on equity of 64.42%. DaVita’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.11 earnings per share. On average, analysts expect DaVita to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

DaVita Price Performance

DVA stock opened at $138.14 on Tuesday. The company has a market capitalization of $12.11 billion, a PE ratio of 18.67, a P/E/G ratio of 1.19 and a beta of 1.04. The company has a current ratio of 1.19, a quick ratio of 1.13 and a debt-to-equity ratio of 6.65. The business’s fifty day moving average price is $132.44 and its 200 day moving average price is $111.30. DaVita has a 12-month low of $71.51 and a 12-month high of $141.54.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on DVA. TheStreet upgraded shares of DaVita from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. UBS Group boosted their price target on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. StockNews.com upgraded DaVita from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 25th. Truist Financial boosted their target price on DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research note on Tuesday, February 20th. Finally, Barclays initiated coverage on DaVita in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 price target on the stock. Two research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, DaVita currently has an average rating of “Moderate Buy” and a consensus price target of $118.50.

Insider Activity

In related news, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the sale, the insider now owns 20,264 shares in the company, valued at $2,424,384.96. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other DaVita news, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $119.64, for a total value of $3,130,260.96. Following the completion of the sale, the insider now owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Kathleen Alyce Waters sold 11,285 shares of the stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $120.73, for a total transaction of $1,362,438.05. Following the completion of the transaction, the insider now owns 81,297 shares of the company’s stock, valued at approximately $9,814,986.81. The disclosure for this sale can be found here. Insiders have sold a total of 134,540 shares of company stock valued at $16,551,071 over the last quarter. Corporate insiders own 1.40% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.